[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study

Journal:

The Lancet Oncology

Published:

2026-03-30

DOI:

10.1016/s1470-2045(26)00017-3

Affiliations:

19

Authors:

30

Go to article

Institutions	Authors	Share
Peter MacCallum Cancer Centre (Peter Mac), Australia	13.500000 13.500000	0.45
The University of Melbourne (UniMelb), Australia	8.166667	0.27
Vancouver Prostate Centre (VPC), Canada	1.500000	0.05
Garvan Institute of Medical Research, Australia	1.166667	0.04
Chris O'Brien Lifehouse, Australia	1.000000	0.03
Monash University, Australia	0.833333	0.03
University of New South Wales (UNSW Sydney), Australia	0.666667	0.02
The Kinghorn Cancer Centre (TKCC), Australia	0.666667	0.02
St Vincent's Hospital Sydney, Australia	0.500000	0.02
Eastern Health, Australia	0.500000	0.02
Princess Alexandra Hospital, Australia	0.500000	0.02
The University of Queensland (UQ), Australia	0.500000	0.02
BC Cancer Research Centre (BCCRC), Canada	0.500000	0.02

Interested in Biomedical Engineering?